Amicus Therapeutics (NASDAQ:FOLD) Stock Quotes, Forecast and News Summary

Q: What sector and industry does Amicus Therapeutics (FOLD) operate in?

Amicus Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Amicus Therapeutics Stock (NASDAQ: FOLD) stock price, news, charts, stock research, profile.

Open	$9.15
Close	$9.19
Volume / Avg.	2.60M / 2.34M
Day Range	$9.02 - $9.26
52 Wk Range	8.79 - 14.02
Market Cap	$2.76B
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	39
Short Interest	5.81%
Days to Cover	9.72

Recent News

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks.

Vandana Singh

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU

Alnylam Pharmaceuticals (NASDAQ: ALNY) announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM).

Zacks

Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug

Amicus Therapeutics enters a license agreement with Teva Pharmaceuticals resolving patent litigation over a generic version of Galafold. Teva may market its version starting in 2037, pending FDA approval. Litigation continues with Aurobindo.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Nov 24

Dec 24

Jan

Feb

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.5

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$9.15
Close	$9.19
Volume / Avg.	2.60M / 2.34M
Day Range	$9.02 - $9.26
52 Wk Range	8.79 - 14.02
Market Cap	$2.76B
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	39
Short Interest	5.81%
Days to Cover	9.72

About Amicus Therapeutics Inc

Sector

Health Care

Industry

Biotechnology

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, develop...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Amicus Therapeutics (FOLD) stock?

You can purchase shares of Amicus Therapeutics (NASDAQ:FOLD) through any online brokerage.

View our list of the best stock brokerages

Who are Amicus Therapeutics (FOLD) competitors?

Other companies in Amicus Therapeutics’s space includes: Immunovant (NASDAQ:IMVT), Twist Bioscience (NASDAQ:TWST), MoonLake (NASDAQ:MLTX), Centessa Pharmaceuticals (NASDAQ:CNTA) and Protagonist Therapeutics (NASDAQ:PTGX).

What is the forecast, or price target, for Amicus Therapeutics (FOLD) stock?

Amicus Therapeutics has a consensus price target of $16.15.

What is the current price for Amicus Therapeutics (FOLD)?

The stock price for Amicus Therapeutics (NASDAQ: FOLD) is $9.19 last updated February 21, 2025 at 4:48 PM EST.

Does Amicus Therapeutics (FOLD) pay a dividend?

There are no upcoming dividends for Amicus Therapeutics.

When is Amicus Therapeutics (NASDAQ:FOLD) reporting earnings?

Amicus Therapeutics’s Q1 earnings are confirmed for Thursday, May 8, 2025.

Is Amicus Therapeutics (FOLD) going to split?

There is no upcoming split for Amicus Therapeutics.

What sector and industry does Amicus Therapeutics (FOLD) operate in?

Amicus Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

Amicus Therapeutics

Amicus Therapeutics (FOLD) Forecast